{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:11:24Z","timestamp":1790784684377,"version":"4.1.0"},"reference-count":89,"publisher":"Informa UK Limited","issue":"16","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline","award":["study 208887"],"award-info":[{"award-number":["study 208887"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.2217\/fon-2020-1269","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T10:14:55Z","timestamp":1615198495000},"page":"1987-2003","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":34,"title":["Belantamab Mafodotin in Combination with Novel Agents in Relapsed\/refractory Multiple Myeloma: DREAMM-5 Study Design"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K","family":"Nooka","sequence":"first","affiliation":[{"name":"Winship Cancer Institute,Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Oncology,Hematology & Bone Marrow Transplantation,University Medical Center of Hamburg-Eppendorf, Hamburg, 20246, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels WCJ","family":"van de Donk","sequence":"additional","affiliation":[{"name":"Department of Hematology,Cancer Center Amsterdam,Amsterdam UMC,Vrije Universiteit Amsterdam, Amsterdam, 1081 \rHV, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Routledge","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, \rVIC \r3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Rodriguez","family":"Otero","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n M\u00e9dica Aplicada,Cl\u00ednica Universidad de Navarra-Pamplona, Navarra, 31008, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital, \rVancouver, \rBC \rV5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Haematology,University of Melbourne,St. Vincent\u2019s Hospital Melbourne, Melbourne, \rVIC 3065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Callander","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center,University of Wisconsin, \rMadison, \rWI \rWI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C","family":"Minnema","sequence":"additional","affiliation":[{"name":"Department of Hematology,University Medical Center Utrecht, Utrecht, 3584 \rCX, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Department of Medicine,Division of Medical Oncology & Hematology,Princess Margaret Cancer Centre, \rToronto, \rON \rM5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A","family":"Jackson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Stockley Park, UB11 1BT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph M","family":"Ahlers","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Im","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinta","family":"Cheng","sequence":"additional","affiliation":[{"name":"SpringWorks Therapeutics, Stamford, CT 06902, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Smith","sequence":"additional","affiliation":[{"name":"SpringWorks Therapeutics, Stamford, CT 06902, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahi","family":"Hareth","sequence":"additional","affiliation":[{"name":"Department of Medicine,Karolinska University Hospital, Stockholm, SE 171 76, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Ferron-Brady","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Brouch","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Montes de Oca","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Paul","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Holkova","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon E","family":"Kremer","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Division of Hematologic Malignancies,Dana-Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122015"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_3_5_5_1","unstructured":"National Cancer Institute. Cancer stat facts: myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0841-y"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16674"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-693606"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-740944"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31680"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000045"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159516"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13046"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0184"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.02.007"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510062"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515626362"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3377-5"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30271-2"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14145"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"e_1_3_5_27_1","first-page":"PF558","volume-title":"24th Congress of the European Hematology Association.","author":"Montes De Oca R","year":"2019","unstructured":"MontesDe Oca R, BhattacharyaS, VitaliNet al.The anti-BCMA antibody\u2013drug conjugate Gsk2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an Ox40 agonist potentiates in vivo activity. In: 24th Congress of the European Hematology Association.Amsterdam, The Netherlands, PF558 (2019)."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00280-8"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_5_32_1","volume-title":"The Society of Hematologic Oncology Annual Meeting (Virtual)","author":"Lonial S","year":"2020","unstructured":"LonialS, LeeC, BadrosAet al.Pivotal DREAMM-2 study: single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors, immunomodulatory agents, and refractory and\/or intolerant to anti-CD38 monoclonal antibodies (mAbs), including subgroups with renal impairment (RI) and high-risk (HR) cytogenetics. Presented at: The Society of Hematologic Oncology Annual Meeting (Virtual) (2020)."},{"key":"e_1_3_5_33_1","unstructured":"BLENREP package insert. (2020). https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Blenrep\/pdf\/BLENREP-PI-MG.PDF"},{"key":"e_1_3_5_34_1","unstructured":"GlaxoSmithKline plc.BLENREP 100 mg powder [summary of product characteristics]. (2020). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blenrep-epar-product-information_en.pdf"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00369-0"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8053"},{"key":"e_1_3_5_37_1","volume-title":"The American Society of Hematology Annual Meeting and Exposition (Virtual).","author":"Popat R","year":"2020","unstructured":"PopatR, NookaA, Stockerl-GoldsteinKet al.DREAMM-6: safety, tolerability, and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib\/dexamethasone (Vd) in relapsed\/refractory multiple myeloma (RRMM). Presented at: The American Society of Hematology Annual Meeting and Exposition (Virtual). (2020)."},{"key":"e_1_3_5_38_1","volume-title":"The American Society of Hematology Annual Meeting and Exposition (Virtual)","author":"Rifkin R","year":"2020","unstructured":"RifkinR, BoydK, GrosickiSet al.DREAMM-7: a Phase III study of the efficacy and safety of belantamab mafodotin with bortezomib and dexamethasone (BVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Presented at: The American Society of Hematology Annual Meeting and Exposition (Virtual). (2020)."},{"key":"e_1_3_5_39_1","unstructured":"Study of belantamab mafodotin plus standard of care (SoC) in newly diagnosed multiple myeloma (DREAMM 9). (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04091126"},{"key":"e_1_3_5_40_1","volume-title":"The American Society of Hematology Annual Meeting and Exposition (Virtual).","author":"Trudel S","year":"2020","unstructured":"TrudelS, DavisR, LewisNet al.DREAMM-8: a Phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Presented at: The American Society of Hematology Annual Meeting and Exposition (Virtual). (2020)."},{"key":"e_1_3_5_41_1","volume-title":"The European Hematology Association Congress (Virtual).","author":"Nooka A","year":"2020","unstructured":"NookaA, MateosManteca M, BahlisNet al.DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin in combination with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM). Presented at: The European Hematology Association Congress (Virtual). (2020)."},{"key":"e_1_3_5_42_1","volume-title":"The American Society for Clinical Oncology Congress (Virtual).","author":"Richardson P","year":"2020","unstructured":"RichardsonP, BiswasS, HolkovaBet al.DREAMM-5 platform trial: belantamab mafodotin in combination with novel agents in patients with relapsed\/refractory multiple myeloma (RRMM). Presented at: The American Society for Clinical Oncology Congress (Virtual). (2020)."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159514"},{"key":"e_1_3_5_46_1","unstructured":"EORTC. QLQ-30. (2020). https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3230"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774510382799"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0210-z"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00766.x"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00034"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4174"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb08211.x"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1089\/1536859041224299"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10831"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-2220"},{"issue":"8","key":"e_1_3_5_57_1","first-page":"viii649","article-title":"Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody","volume":"29","author":"Brett S","year":"2018","unstructured":"BrettS, YadavilliS, Seestaller-WehrLet al.Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. ESMO 29(Suppl. 8), viii649\u2013viii669 (2018).","journal-title":"ESMO"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.75"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14356"},{"key":"e_1_3_5_60_1","volume-title":"The European Society for Medical Oncology Congress.","author":"Hansen A","year":"2018","unstructured":"HansenA, BauerT, MorenoVet al.First in human study with GSK3359609 [GSK609], inducible t cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: preliminary results from INDUCE-1. Presented at: The European Society for Medical Oncology Congress.Munich, Germany (2018)."},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0607"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.1994"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607265"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123705"},{"key":"e_1_3_5_67_1","unstructured":"Spring Works Therapeutics Inc. https:\/\/www.springworkstx.com\/pipeline\/nirogacestat\/#:~:text=Nirogacestat"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01088"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3638"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0428"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"issue":"8","key":"e_1_3_5_73_1","first-page":"viii332","article-title":"Preliminary safety, efficacy, and pharmacokinetic\/pharmacodynamic characterization from GARNET, a Phase I\/II clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H and MSS endometrial cancer","volume":"29","author":"Oaknin A","year":"2019","unstructured":"OakninA, EllardS, LeathIii Cet al.Preliminary safety, efficacy, and pharmacokinetic\/pharmacodynamic characterization from GARNET, a Phase I\/II clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H and MSS endometrial cancer. SGO Annual Meeting 29(Suppl. 8), viii332\u2013viii358 (2019).","journal-title":"SGO Annual Meeting"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.310"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15946"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14340"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001821"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-775122"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061473"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12242"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0034-3"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40320-5_10"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-1269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:47:04Z","timestamp":1719125224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-1269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":89,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.2217\/fon-2020-1269"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-1269","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}